Flying The Web For News.
Featured Guest Posts
Dropshipping Guide
Shopify E-commerce Guide
Microsoft Exam Study
Business Opportunity Ideas
Microsoft Jobs News
Microsoft Exam
Writing Service Review
Slot Game Review
Data Recovery Review
Publicaciones Destacadas
Como ganar dinero por Internet
+ Larger Font | - Smaller Font
Share


COVID-19 Map Tracker | COVID-19 News Features


Globe NewsWire News Distribution Service


TOKYO and CAMBRIDGE, United Kingdom, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in G protein-coupled receptor (GPCR) focused structure-based drug design (SBDD) and development, has been notified by its partner Neurocrine Biosciences Inc. (“Neurocrine”; Nasdaq: NBIX) that the U.S. Food and Drug Administration (FDA) Investigational New…


Posted: 2022-08-04 23:05:00

Get Full News Story On GlobeNewsWire Press Release Service



Listen to this article. Speaker link opens in a new window.
Text To Speech BETA Test Version.



Related News Stories From The Web And More

Related Bing News Search Results

Press Release: Sosei Heptares’ Oral, Selective M4 Receptor Agonist Advancing into Phase 2 Clinical Development under Multi-Program Collaboration with Neurocrine Biosciences - Newscast

Voyager Therapeutics Prioritizes Pipeline And Reports Second Quarter 2022 Financial And Operating Results

Thu, 04 Aug 2022 14:07:00 GMT Pipeline prioritizes tau antibody for Alzheimer's disease and gene therapies for GBA1 Parkinson's disease and SOD1 ALS, each program ... costs under the Neurocrine collaboration, will be ...

Voyager Therapeutics Prioritizes Pipeline and Reports Second Quarter 2022 Financial and Operating Results

Thu, 04 Aug 2022 13:25:00 GMT This review identified a compelling opportunity for each prioritized program based on the following ... for development costs under the Neurocrine collaboration, will be sufficient to meet ...

Neurocrine Biosciences Reports Second Quarter 2022 Financial Results and Raises 2022 INGREZZA Sales Guidance

Thu, 04 Aug 2022 13:05:00 GMT Neurocrine Biosciences disclaims any obligation to update the statements contained in this press release after the date hereof. (Loss) income before (benefit from) provision for income taxes (23.3 ...

Voyager Therapeutics Prioritizes Pipeline and Reports Second Quarter 2022 Financial and Operating Results

Thu, 04 Aug 2022 13:03:00 GMT Pipeline prioritizes tau antibody for Alzheimer’s disease and gene therapies for GBA1 Parkinson’s disease and SOD1 ALS, each program employing efficient paths to human proof of biology Targeting ...

Idorsia announces financial results for the first half 2022 - reaching commercial stage

Mon, 25 Jul 2022 23:00:00 GMT LR Idorsia Ltd (SIX: IDIA) today announced its financial results for the first half of 2022. QUVIVIQ(TM) (daridorexant) was launched in the US in May 2022 and is building positive early momentum in ...

Related News Story Videos From Youtube



Blow Us A Whistle